REG - CVS Group plc - Response to CMA provisional decision announcement

CVSAnnouncement

Yesterday 07:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251015:nRSO4631Da&default-theme=true

RNS Number : 4631D  CVS Group plc  15 October 2025

For immediate release
 
 
        15 October 2025

 

CVS Group plc

("CVS" or the "Company" and, together with its subsidiaries, the "Group")

 

Response to CMA provisional decision announcement

 

 

CVS notes this morning's publication by the Competition and Markets Authority
("CMA") of the summary of its provisional decision in the veterinary market
investigation. The CMA is expected to publish its full provisional decision
later today.

 

CVS welcomes the additional certainty that this morning's announcement brings.
We will be responding to the provisional decision and proposed remedies
package in writing in due course and have a further hearing with the CMA in
December 2025. We look forward to the publication of the final decision in
March 2026 and conclusion of this market investigation promptly thereafter.

 

We are pleased to see that the CMA has considered our and the veterinary
profession's feedback on the initial 28 remedies proposed in May 2025, which
have been refined to 21 with no new remedies introduced. Whilst we do not
believe that all of these remedies are fully justified, we will be working
with the CMA to refine the remedies package to ensure it is workable and
deliverable and have plans in place to implement them, including joint
branding of our practices and the publishing of standardised price lists.

 

As such, the Board continues to expect the Group to trade in line with market
expectations.

 

Contacts

CVS Group plc
 
 
         via Camarco

Richard Fairman, Chief Executive Officer

Robin Alfonso, Chief Financial Officer

Paul Higgs, Chief Veterinary Officer

Charlotte Page, Head of Investor Relations

 

Peel Hunt LLP (Nominated Adviser & Joint
Broker)
 
           +44 (0)20 7418 8900

Christopher Golden / James Steel / Andrew Clark

 

Berenberg (Joint
Broker)
                            +44 (0)20 3207 7800

Toby Flaux / Michael Burke / Milo Bonser / Brooke Harris-Lowing

 

Camarco (Financial
PR)

Ginny Pulbrook
 
 
        cvsg@camarco.co.uk (mailto:cvsg@camarco.co.uk)

Letaba Rimell

Tilly Butcher

 

About CVS Group plc (www.cvsukltd.co.uk)

 

CVS Group is an AIM-listed provider of veterinary services with operations in
the UK and Australia.  CVS is focused on providing high-quality clinical
services to its clients and their animals, with outstanding and dedicated
clinical teams and support colleagues at the core of its strategy.

 

The Group now operates c.470 veterinary practices across its two territories,
including specialist referral hospitals and dedicated out-of-hours sites.
Alongside the core Veterinary Practices division, CVS operates Laboratories
(providing diagnostic services to CVS and third-parties) and an online retail
business ("Animed Direct").

 

The Group employs c.8,900 personnel, including c.2,400 veterinary surgeons and
c.3,300 nurses.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RSPFFLSMIEISEDS



            Copyright 2019 Regulatory News Service, all rights reserved